Skip to content
10-K/A

Annual Report

Regenicin, Inc.

0001662252-22-000015

← back to feed
Filed
Mar 25, 2022 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · Dec 31, 2021 153.48M sh
Shares Diluted FY 2021 · Sep 30, 2021 153.48M sh
Shares Diluted FY 2021 · Sep 30, 2020 153.48M sh
Operating Cash Flow restated FY 2021 · Sep 30, 2021 −$24.11K
Operating Cash Flow restated FY 2021 · Sep 30, 2020 −$123.2K
Stockholders Equity restated FY 2021 · Sep 30, 2021 −$4.96M
Stockholders Equity restated FY 2021 · Sep 30, 2020 −$4.29M
Stockholders Equity restated FY 2021 · Sep 30, 2019 −$3.73M
Current Liabilities restated FY 2021 · Sep 30, 2021 $4.96M
Current Liabilities restated FY 2021 · Sep 30, 2020 $4.29M
Total Assets restated FY 2021 · Sep 30, 2021 $4.61K
Total Assets restated FY 2021 · Sep 30, 2020 $4.14K
Sga Expense restated FY 2021 · Sep 30, 2021 $635.86K
Sga Expense restated FY 2021 · Sep 30, 2020 $663.75K
Net Income restated FY 2021 · Sep 30, 2021 −$670.6K
Net Income restated FY 2021 · Sep 30, 2020 −$559.59K
Operating Income restated FY 2021 · Sep 30, 2021 −$635.86K
Operating Income FY 2021 · Sep 30, 2020 −$510.82K